(IN BRIEF) AstraZeneca's Tagrisso receives FDA approval for treating adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung…
(IN BRIEF) AstraZeneca's supplemental New Drug Application (sNDA) for Tagrisso (osimertinib) in combination with chemotherapy has been granted Priority Review…
(IN BRIEF) GSK has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the…
(PRESS RELEASE) BRISTOL, 19-Apr-2022 — /EuropaWire/ — University of Bristol, a red brick research university, has announced that it led…
(PRESS RELEASE) CAMBRIDGE, 24-Sep-2021 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British–Swedish multinational pharmaceutical and biopharmaceutical company, has announced positive…
Application is being reviewed under the US FDA’s Real-Time Oncology Review pilot programme Based on results of the Phase III IMpower010…
(PRESS RELEASE) SOPHIA ANTIPOLIS CEDEX, France, 12-Apr-2021 — /EuropaWire/ — EuroCMR 2021 will highlight how magnetic resonance imaging (MRI) of…
Financing deal worth €15.0 million signed to support clinical development programme for masitinib Masitinib developed as a credible candidate for treating…
(PRESS RELEASE) THE HAGUE, 19-Jun-2020 — /EuropaWire/ — The Dutch Research Council (NWO) has announced that six researchers will receive…
The new immunotherapy will be tested in humans as soon as possible (PRESS RELEASE) ZURICH, 8-May-2020 — /EuropaWire/ — University…
SOUTHAMPTON, 02-Apr-2018 — /EuropaWire/ — Many patients receiving chemotherapy following surgery for bowel cancer may only need three months treatment rather…
BASEL, 20-Mar-2018 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower131 study met its…
Imfinzi is the only immunotherapy approved for patients with unresectable Stage III non-small cell lung cancer Imfinzi showed an 11.2…
LIVERPOOL, 25-Nov-2016 — /EuropaWire/ — A pioneering University of Liverpool research team have published a study that identifies the mechanism…